SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001493152-22-031139
Filing Date
2022-11-09
Accepted
2022-11-09 17:00:45
Documents
13
Period of Report
2022-11-03
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 37947
2 ex3-1.htm EX-3.1 157778
  Complete submission text file 0001493152-22-031139.txt   407679

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE gtbp-20221103.xsd EX-101.SCH 3236
4 XBRL LABEL FILE gtbp-20221103_lab.xml EX-101.LAB 34240
5 XBRL PRESENTATION FILE gtbp-20221103_pre.xml EX-101.PRE 22365
7 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3704
Mailing Address 8000 MARINA BLVD SUITE 100 BRISBANE CA 94005
Business Address 8000 MARINA BLVD SUITE 100 BRISBANE CA 94005 (800) 304-9888
GT Biopharma, Inc. (Filer) CIK: 0000109657 (see all company filings)

IRS No.: 941620407 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40023 | Film No.: 221373525
SIC: 2834 Pharmaceutical Preparations